financetom
Business
financetom
/
Business
/
Terra Chips Maker Hain Celestial Q2: Earnings Miss, Supply Chain Snags, Outlook Cut And More
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Terra Chips Maker Hain Celestial Q2: Earnings Miss, Supply Chain Snags, Outlook Cut And More
Feb 10, 2025 7:14 AM

Shares of food and personal-care company Hain Celestial Group Inc ( HAIN ) are trading lower on Monday following the second-quarter earnings result.

The company reported a second-quarter sales decline of 9.4% year-on-year to $411.49 million, missing the analyst consensus estimate of $431.55 million.

Organic net sales from North America decreased 9% Y/Y, driven primarily by lower sales in snacks due to in-store marketing activation and promotion effectiveness as well as by lower sales in personal care.

International organic sales declined 4%, due primarily to lower sales in meal prep and short-term service challenges.

Adjusted gross margin for the quarter contracted 60 basis points Y/Y to 22.9%. The operating loss for the quarter was $91.8 million versus a loss of $0.8 million last year.

Also Read: Software Company SolarWinds Agrees To Go Private In $4.4B Deal

Adjusted EBITDA was $38 million compared to $47 million in the prior year period. Adjusted EBITDA margin was 9.2%, compared to 10.4% in the prior year period.

Adjusted EPS of $0.08 missed the consensus estimate of $0.12.

The company held $56.2 million in cash and equivalents as of December 31, 2024. Operating cash flow for the quarter was $31 million, with a free cash flow of $25 million.

Net debt at the end of the fiscal second quarter was $672 million compared to $690 million at the beginning of the fiscal year.

“Commercial execution and supply chain challenges drove second quarter results that were below our expectations. We have already taken steps to address these challenges and remain focused on disciplined execution. Recent distribution wins and the recovery of our infant formula supply bolster our belief that we are well positioned to pivot to growth in the back half of the year, however given performance to date and the challenging macroeconomic backdrop we are adjusting our full year outlook,” stated Lee Boyce, CFO.

Outlook: Hain Celestial ( HAIN ) sees FY25 organic net sales down 2%—4%, down from the prior view of flat or better organic net sales growth.

Adjusted EBITDA is expected to be flat year-on-year (prior view: grow by mid-single digits). Hain Celestial ( HAIN ) sees gross margin to improve by at least 90 basis points (prior view: increase by at least 125 basis points).

Price Action: HAIN shares are trading lower by 21.9% at $3.665 at the last check Monday.

Read Next:

Intuit’s AI, Market Expansion Position It For Long-Term Growth

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
RumbleOn Appoints Michael Quartieri CEO, Cameron Tkach COO
RumbleOn Appoints Michael Quartieri CEO, Cameron Tkach COO
Jan 14, 2025
04:01 AM EST, 01/14/2025 (MT Newswires) -- RumbleOn ( RMBL ) said late Monday it has appointed Michael Quartieri chief executive officer. Quartieri serves as the chairman of the company's board and succeeds CEO Michael Kennedy. The company also promoted Cameron Tkach, vice president of dealership operations, to chief operating officer. The leadership changes became effective on Monday. ...
Merit Medical Systems Poised to Report Revenue Growth in 2024; Shares Jump Premarket
Merit Medical Systems Poised to Report Revenue Growth in 2024; Shares Jump Premarket
Jan 14, 2025
04:23 AM EST, 01/14/2025 (MT Newswires) -- Merit Medical Systems ( MMSI ) said late Monday it expects revenue of about $1.355 billion to $1.357 billion for the year ended Dec. 31, a projected increase of about 7.7% to 7.9% from a year earlier. Analysts polled by FactSet expect $1.348 billion. Shares of the company rose more than 7% in...
Vaxart Says Oral Covid-19 Vaccine Candidate Recommended for Continued Study
Vaxart Says Oral Covid-19 Vaccine Candidate Recommended for Continued Study
Jan 14, 2025
04:09 AM EST, 01/14/2025 (MT Newswires) -- Vaxart ( VXRT ) said late Monday an independent data safety monitoring board has recommended that a phase 2b trial of its oral Covid-19 vaccine candidate continue without any modifications. The company said the US Food and Drug Administration is reviewing the safety data from the study. Upon favorable review, the company will...
Hutchmed Says Orpathys Receives Full Approval in China
Hutchmed Says Orpathys Receives Full Approval in China
Jan 14, 2025
04:20 AM EST, 01/14/2025 (MT Newswires) -- Hutchmed ( HCM ) said late Monday that China's National Medical Products Administration has approved its supplemental new drug application for Orpathys to treat certain adult patients with non-small cell lung cancer. The drugmaker said the regulator also converted Orpathys' prior conditional approval for previously treated patients to full approval. The updated label...
Copyright 2023-2026 - www.financetom.com All Rights Reserved